ERIS - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.9
| Stock Code | ERIS | Market Cap | 17,786 Cr. | Current Price | 1,286 ₹ | High / Low | 1,910 ₹ |
| Stock P/E | 59.9 | Book Value | 203 ₹ | Dividend Yield | 0.57 % | ROCE | 6.86 % |
| ROE | 3.02 % | Face Value | 1.00 ₹ | DMA 50 | 1,395 ₹ | DMA 200 | 1,492 ₹ |
| Chg in FII Hold | -0.36 % | Chg in DII Hold | 0.95 % | PAT Qtr | 17.0 Cr. | PAT Prev Qtr | 150 Cr. |
| RSI | 36.2 | MACD | -28.5 | Volume | 73,181 | Avg Vol 1Wk | 1,07,458 |
| Low price | 1,097 ₹ | High price | 1,910 ₹ | PEG Ratio | -1.38 | Debt to equity | 0.79 |
| 52w Index | 23.2 % | Qtr Profit Var | 853 % | EPS | 20.8 ₹ | Industry PE | 27.2 |
📊 ERIS shows weak potential for intraday trading today. Momentum indicators (RSI 36.2, MACD -28.5) are bearish, and volume is below the 1-week average, suggesting limited upside. Fundamentals are also weak with low ROCE (6.86%) and ROE (3.02%), while valuation remains expensive (P/E 59.9 vs industry 27.2). Intraday trades should be approached with caution and tight stop-losses.
💰 Optimal Buy Price: 1,270–1,290 ₹ (near support)
📈 Profit-Taking Exit Levels: 1,310–1,330 ₹ (short-term resistance)
📉 Stop-Loss: 1,260 ₹ (below immediate support)
⏳ If Already Holding: Exit if price fails to sustain above 1,300 ₹ or if intraday volume remains weak. Momentum suggests quick profit booking on minor rallies rather than holding for extended moves.
✅ Positive
- DII holdings increased (+0.95%), showing domestic institutional support.
- EPS at 20.8 ₹ reflects profitability despite weak returns.
- Dividend yield of 0.57% adds shareholder value.
- Stock has rebounded 23.2% from its 52-week low, showing resilience.
⚠️ Limitation
- Current price (1,286 ₹) is below both DMA 50 (1,395 ₹) and DMA 200 (1,492 ₹), showing weak trend alignment.
- RSI (36.2) and MACD (-28.5) indicate bearish momentum.
- Volume (73,181) is lower than 1-week average (1,07,458), limiting intraday strength.
- High debt-to-equity ratio (0.79) compared to peers.
📉 Company Negative News
- PAT dropped sharply to 17 Cr. from 150 Cr., showing earnings pressure.
- FII holdings decreased (-0.36%), reflecting reduced foreign investor confidence.
- PEG ratio (-1.38) indicates valuation concerns relative to growth.
📈 Company Positive News
- Quarterly profit variation (+853%) shows operational improvement despite low PAT base.
- Dividend yield provides consistent shareholder returns.
🏭 Industry
- Industry PE is 27.2, lower than company PE (59.9), indicating ERIS trades at a premium.
- Pharmaceutical sector outlook remains stable with long-term demand resilience.
🔎 Conclusion
ERIS offers weak intraday trading potential due to poor momentum, low volume, and expensive valuation. Strong fundamentals are lacking, and earnings have declined sharply. Traders should be cautious, using tight stop-losses and quick profit booking. Long-term investors may wait for fundamental recovery before considering entry.